Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis

For allergen immunotherapy (AIT) to be effective, it should be high dose. However, after reviewing the data on AIT dosing, one can conclude that, especially for sublingual AIT (SL-AIT), products should not only be compared on the basis of their allergen content. Clinical trial outcomes seem the best parameter. However, comparing products' performances expressed in percentages of improvement in different trials is not scientifically sustainable because of the many trial-related variables, as we review here.

from #ENT via xlomafota13 on Inoreader http://ift.tt/1TvkHkp
via IFTTT